Comparative Pharmacology
Head-to-head clinical analysis: AEMCOLO versus NITROFURANTOIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEMCOLO versus NITROFURANTOIN.
AEMCOLO vs NITROFURANTOIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEMCOLO (crizotinib) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and mesenchymal-epithelial transition factor (MET). It inhibits ALK and ROS1 phosphorylation, blocking downstream signaling pathways involved in cell proliferation and survival.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inactivate or inhibit bacterial ribosomal proteins, DNA, RNA, and metabolic enzymes, leading to bacterial cell death.
AEMCOLO (rifamycin) delayed-release tablets: 600 mg orally twice daily for 3 days. Take with or without food.
100 mg orally twice daily for 5-7 days (uncomplicated UTI); 50-100 mg orally four times daily for 7 days (symptomatic uncomplicated UTI). Extended-release: 100 mg orally twice daily for 7 days.
None Documented
None Documented
Clinical Note
moderateNitrofurantoin + Norfloxacin
"The therapeutic efficacy of Norfloxacin can be decreased when used in combination with Nitrofurantoin."
Clinical Note
moderateNitrofurantoin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Nitrofurantoin."
Clinical Note
moderateNitrofurantoin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Nitrofurantoin."
Clinical Note
moderateNitrofurantoin + Rolapitant
Terminal elimination half-life is approximately 18-22 hours, supporting once-daily dosing for maintained intraluminal concentrations.
Normal renal function: 20-60 minutes; impaired function: prolonged up to 1-2 hours, clinically significant due to urinary concentration requirement
Primarily fecal elimination as unchanged drug; approximately 90% of a dose is recovered in feces, with less than 1% excreted unchanged in urine. Biliary excretion accounts for the remainder.
Renal: ~40% unchanged via glomerular filtration and tubular secretion, biliary/fecal: <1%
Category C
Category D/X
Antibiotic
Antibiotic
"The serum concentration of Rolapitant can be increased when it is combined with Nitrofurantoin."